Apogee Therapeutics, Inc. (APGE)
134.81
+0.06
(+0.04%)
USD |
NASDAQ |
Aug 24, 16:00
134.81
0.00 (0.00%)
After-Hours: 19:17
Apogee Therapeutics Shareholders Equity (Quarterly) : 1.195B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.195B |
| March 31, 2026 | 1.256B |
| December 31, 2025 | 903.88M |
| September 30, 2025 | 586.34M |
| June 30, 2025 | 619.40M |
| March 31, 2025 | 673.36M |
| December 31, 2024 | 716.79M |
| September 30, 2024 | 734.40M |
| Date | Value |
|---|---|
| June 30, 2024 | 773.64M |
| March 31, 2024 | 801.48M |
| December 31, 2023 | 379.91M |
| September 30, 2023 | 409.24M |
| June 30, 2023 | 113.05M |
| March 31, 2023 | 130.82M |
| December 31, 2022 | 142.08M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | 532.39M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Intellia Therapeutics, Inc. | 727.71M |
| Revolution Medicines, Inc. | 2.606B |
| Erasca, Inc. | 361.87M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.336B |
| Total Liabilities (Quarterly) | 141.21M |
| Debt to Equity Ratio | 0.0888 |
| Current Ratio | 26.44 |
| Net Debt Paydown Yield | -0.19% |